The development of busulfan/cyclophosphamide preparative regimens.

Abstract:

:Bone marrow transplantation (BMT) preparative regimens consisting of busulfan (Bu) and cyclophosphamide (Cy) were developed as an alternative to preparative regimens based on total body irradiation (TBI). Animal studies demonstrated that Bu had a high level of myeloablative and antileukemic activity, but little immunosuppressive effect. In contrast, Cy was sufficiently immunosuppressive to allow allogeneic marrow engraftment in animal systems. In both animals and humans, the combination of Bu and Cy results in effective eradication of the host's bone marrow and suppression of the immune response, thus allowing engraftment by either allogeneic or autologous marrow. A number of BMT preparative regimens have been developed for use in leukemic patients. These regimens differ primarily in the myeloablative agent used (Bu or TBI) and the dose of Cy. Although few comparative studies have been conducted, BuCy regimens appear to be similar in efficacy to those containing Cy and TBI. In addition to its use in leukemic patients, BuCy BMT preparative regimens also have been used in patients with nonmalignant lymphohematopoietic disorders or other malignant diseases.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Santos GW

subject

Has Abstract

pub_date

1993-08-01 00:00:00

pages

12-6; quiz 17

issue

4 Suppl 4

eissn

0093-7754

issn

1532-8708

journal_volume

20

pub_type

杂志文章,评审
  • Lymphoma and myeloma in older patients.

    abstract::Lymphoma and myeloma represent an increasingly important cause of morbidity and mortality in the older patient group. Studies to date, while limited, suggest that there may be differences in the underlying biology of the tumor cell of some lymphoid malignancies in younger versus older patients. Significant new data wi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.12.030

    authors: Westin EH,Longo DL

    更新日期:2004-04-01 00:00:00

  • The Veterans Precision Oncology Data Commons: Transforming VA data into a national resource for research in precision oncology.

    abstract::The Department of Veterans Affairs (VA) has a strong track record providing high-quality, evidence-based care to cancer patients. In order to accelerate discoveries that will further improve care for Veterans with cancer, the VA has partnered with the Center for Translational Data Science at the University of Chicago ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2019.09.002

    authors: Do N,Grossman R,Feldman T,Fillmore N,Elbers D,Tuck D,Dhond R,Selva L,Meng F,Fitzsimons M,Ajjarapu S,Ayandeh S,Hall R,Do S,Brophy M

    更新日期:2019-01-01 00:00:00

  • Single-agent oral etoposide for elderly small cell lung cancer patients.

    abstract::Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

    更新日期:1990-02-01 00:00:00

  • Cyclooxygenase-2 inhibitors in colorectal cancer.

    abstract::Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory dr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00120-9

    authors: Stoehlmacher J,Lenz HJ

    更新日期:2003-06-01 00:00:00

  • Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.

    abstract::The side effects of cisplatin (75 mg/m2) in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (175 mg/m2 over 3 hours) are expected to be more severe and frequent than those of carboplatin (area under the concentration-time curve of 5) in combination with the same dose of paclitaxel, but...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Neijt JP,Engelholm SA,Witteveen PO,Tuxen MK,Sørensen PG,Hansen M,Hirsch F,Sessa C,de Swart C,van Houwelingen HC,Lund B,Hansen SW

    更新日期:1997-10-01 00:00:00

  • Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas.

    abstract::The results of adjuvant chemotherapy in high-grade gliomas are disappointing. Carmustine (BCNU) wafers placed in the resection cavity provide a modest increase in median survival. However, the overall benefit of this approach is small, it offers no potential for cure, and the results are not statistically significant ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.035

    authors: Grossman SA

    更新日期:2003-12-01 00:00:00

  • Fatigue: definitions, mechanisms, and paradigms for study.

    abstract::Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalakas MC,Mock V,Hawkins MJ

    更新日期:1998-02-01 00:00:00

  • Cellular immunotherapy and cancer.

    abstract::Recent data indicate that cellular immune responses can produce an anticancer effect. Two types of cellular immune responses appear to be clinically relevant: antigen specific immunity mediated by T cells that recognize tumor-associated peptide antigen expressed on surface HLA class I or class II molecules, and antige...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.02.021

    authors: Waller EK

    更新日期:2004-04-01 00:00:00

  • Epidemiology of bone and soft tissue sarcomas.

    abstract::Although bone and soft tissue sarcomas are not common, a significant number of patients who develop these tumors will die with metastatic disease. Part of the reason is that many of the patients have advanced disease at diagnosis. Identification of an etiologic agent should allow for diagnosis at an earlier stage. Thi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: McClay EF

    更新日期:1989-08-01 00:00:00

  • Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review.

    abstract::Follicular lymphoma is a low-grade, indolent non-Hodgkin's lymphoma characterized by the presence of the t(14;18) translocation. The detection of this translocation using polymerase chain reaction techniques has been increasingly studied. However, the diagnostic and prognostic value of detecting t(14;18) rearrangement...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Bordeleau L,Berinstein NL

    更新日期:2000-12-01 00:00:00

  • Phase II and III studies with carboplatin in small cell lung cancer.

    abstract::Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC) (11% complete response [CR], 59% CR plus partial response [PR]). Combination carboplatin/etoposide/vincristine (CEV) (phase II trial) led to an overall remission rate of 84% in patients with limited disease (LD), with 52% CRs. The ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Gatzemeier U,Hossfeld DK,Neuhauss R,Reck M,Achterrath W,Lenaz L

    更新日期:1992-02-01 00:00:00

  • Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?

    abstract::A wide variety of cytogenetic abnormalities and molecular pathways have been implicated in the pathogenesis of sarcoma, and significant progress has been made in the past decade toward identifying potential therapeutic targets. However, apart from gastrointestinal stromal tumors (GISTs) and dermatofibrosarcoma protube...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.09.003

    authors: Riedel RF

    更新日期:2011-10-01 00:00:00

  • Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

    abstract::Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San Francisco, CA) is a genetically engineered monoclonal antibody for the treatment of non-Hodgkin's lymphoma. This chimeric mouse/human, immunoglobulin GI kappa anti-CD20 antibody mediates complement-dependent cell lysis and antibody-depend...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Grillo-López AJ,White CA,Varns C,Shen D,Wei A,McClure A,Dallaire BK

    更新日期:1999-10-01 00:00:00

  • Liver-directed therapies in colorectal cancer.

    abstract::The liver is the most common site of metastatic colorectal cancer (CRC) and the status of this organ is an important determinant of overall survival in patients with advanced disease. Complete resection of hepatic CRC metastases can provide a long-term cure for some patients, but the majority of liver metastases are n...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.025

    authors: Ruan DT,Warren RS

    更新日期:2005-02-01 00:00:00

  • Cardio-oncology in clinical studies and real life.

    abstract::Session V of the Colloquium was chaired by Professors Teresa López-Fernández of Spain and Grzegorz Opolski of Poland. The 3 speakers addressed cardio-oncology issues as they relate to both clinical studies and real life situations. Professor Susan Dent discussed cardio-oncology networks for patients, emphasizing the i...

    journal_title:Seminars in oncology

    pub_type:

    doi:10.1053/j.seminoncol.2019.01.004

    authors: Dent SF,Suter TM,López-Fernández T,Opolski G,Menna P,Minotti G

    更新日期:2019-12-01 00:00:00

  • The application of genetics and genomics to cancer prevention.

    abstract::Advances in technology have accelerated the translation of genetics and genomics into the arena of cancer prevention. This provides unique opportunities to individualize cancer risk prediction so early intervention can either modify risk or allow for early diagnosis thereby potentially decreasing the morbidity and mor...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.05.005

    authors: Calzone K,Wattendorf D,Dunn BK

    更新日期:2010-08-01 00:00:00

  • New antimetabolites in the treatment of human malignancies.

    abstract::Several new antimetabolites have been evaluated in clinical trials in recent years. Those with the most promising activity include the structurally related purine analogs fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin. These compounds have shown impressive activity against a broad spectrum of indolent lym...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Cheson BD

    更新日期:1992-12-01 00:00:00

  • Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea.

    abstract::Preclinical studies have indicated that hydroxyurea leads to enhancement of 5-fluorouracil (5-FU) activity when given after 5-FU. This is presumably due to hydroxyurea's actions resulting in maintaining low levels of deoxyuridine monophosphate pools. The combination of hydroxyurea and 5-FU has been tested in several i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Muggia FM,Moran RG

    更新日期:1992-06-01 00:00:00

  • High-dose megestrol acetate in the treatment of advanced breast cancer.

    abstract::A dose-response relationship has long been suspected for progestin compounds in the treatment of breast cancer, but only recently have trials been implemented to investigate this issue. In 1985, we began a phase I-II study of high-dose megestrol acetate in dosages of 480 mg/d to 1,600 mg/d in heavily pretreated postme...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Tchekmedyian NS,Tait N,Abrams J,Aisner J

    更新日期:1988-04-01 00:00:00

  • Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial.

    abstract::Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment schedule was red...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Steinke B,Günther E,Hirschmann WD,Sondern W,Koniczek KH,Wander HE,Natt F,Wagner T,Hinrichs HF,Werdier D

    更新日期:1992-04-01 00:00:00

  • Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.

    abstract::The discovery of the HER2/neu proto-oncogene and its role in the pathogenesis of breast cancer tumors, and the development of the anti-HER2 monoclonal antibody, trastuzumab (Herceptin; Genentech, South San Francisco, CA), directed against the HER2 receptor represent major milestones in the research developments in bre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90188-5

    authors: Slamon D,Pegram M

    更新日期:2001-02-01 00:00:00

  • The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.

    abstract::The Wayne State University Waldenstrom's Macroglobulinemia xenograft model in mice with severe combined immune deficiency (WSU-WM-SCID) is the only preclinical animal model available for this disease. It is based on a permanent, EBV- IgMlambda cell line (WSU-WM) established from a patient with a 10-year history of Wal...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/sonc.2003.50043

    authors: Al-Katib AM,Mensah-Osman E,Aboukameel A,Mohammad R

    更新日期:2003-04-01 00:00:00

  • Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.

    abstract::This phase I trial was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin (400 mg/m2) as first-line chemotherapy for stage IIIC/IV ovarian adenocarcinoma. After premedication, paclitaxel was infu...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lhommé C,Kerbrat P,Lejeune C,Guastalla JP,Fumoleau P,Goupil A,Héron JF,Cassin MA,Pruvot I,Soares JA,Chazard M

    更新日期:1996-10-01 00:00:00

  • Non-small cell lung cancer treatment-related bone marrow toxicities.

    abstract::A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may al...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.03.014

    authors: Ettinger DS

    更新日期:2005-04-01 00:00:00

  • Psychosocial and sexual functioning of survivors of breast cancer.

    abstract::The literature documents that the majority of breast cancer survivors have adjusted well after their first 2 years since diagnosis. However, there is a subset of survivors reporting psychological distress, including depression and anxiety, involving approximately 30% by 4 years post-treatment, but widely ranging from ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.08.025

    authors: Kornblith AB,Ligibel J

    更新日期:2003-12-01 00:00:00

  • Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.

    abstract::Hypoxic areas are a characteristic property of solid tumors. Hypoxia results from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the emergence of hypoxia are (1) structural and functional abnormalities in the tumor microvasculature; (2) an increase in diffusion distances; ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90210-6

    authors: Vaupel P,Kelleher DK,Höckel M

    更新日期:2001-04-01 00:00:00

  • Radiation therapy in pregnancy: risk calculation and risk minimization.

    abstract::The benefits of radiation therapy (RT) as part of a treatment regimen for cancer must be weighed against the potential risk of harm to the patient and in the pregnant patient, the risk to the developing fetus. Information necessary for determining the potential effects of RT on the developing fetus include the gestati...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Greskovich JF Jr,Macklis RM

    更新日期:2000-12-01 00:00:00

  • Diagnosis and prevention of gastrointestinal malignancies.

    abstract::The consistently high mortality rates associated with gastrointestinal cancer result in large part from malignancies that progress undetected to an advanced stage of disease when treatment is usually less effective. In response to this fact, increasing attention has been directed toward developing methods of both prim...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Winawer SJ

    更新日期:1991-02-01 00:00:00

  • Autoimmune complications of chronic lymphocytic leukemia.

    abstract::Autoimmune complications are common in chronic lymphocytic leukemia (CLL), occurring in up to a quarter of all patients during the course of the illness. By far the most common manifestation is autoimmune hemolytic anemia (AIHA), followed by immune thrombocytopenia (ITP). It is not true to say that autoimmunity is con...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.01.011

    authors: Hamblin TJ

    更新日期:2006-04-01 00:00:00

  • Small cell carcinoma of the head and neck: a review.

    abstract::Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck. Excluding cases that are considered to arise from skin, SCC in the head and neck has been found to develop in nearly all structures associated wit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.10.024

    authors: Renner G

    更新日期:2007-02-01 00:00:00